Format

Send to

Choose Destination
Pathol Res Pract. 2019 Oct;215(10):152572. doi: 10.1016/j.prp.2019.152572. Epub 2019 Aug 1.

NTRK-Fusions - A new kid on the block.

Author information

1
Institute of Pathology and Molecular Diagnostics, University Clinic Augsburg, Germany. Electronic address: bruno.maerkl@uk-augsburg.de.
2
II. Medical Clinic, University Clinic Augsburg, Germany.
3
Institute of Pathology and Molecular Diagnostics, University Clinic Augsburg, Germany.

Abstract

The neurotrophic tyrosine receptor kinases (NTRK) play an important role in the development and function of the nervous system. Fusions involving NTRK and a wide range of genes that act as fusion partners are oncogenic and activate well-known signal transduction pathways like the MAPK-ERK pathway. NTRK fusions occur in many very different tumor entities in children and youth as well as in adults. There are a few tumors like secretory breast cancer and congenital fibrosarcoma for which NTRK fusions are pathognomonic. At the same time there a large number of tumors in which NTRK fusions occur in very rare frequency (e.g., lung cancer). TRK inhibitors offer now the possibility to use NTRK fusion as antitumorigenic targets in a tumor agnostic fashion regardless of the basic histology. It is the task of modern pathology to identify such targetable fusions in a highly effective and efficient manner.

KEYWORDS:

NTRK; NTRK fusions; Neurotrophic tyrosine receptor kinases; TRK inhibitor; Tumor agnostic

PMID:
31400924
DOI:
10.1016/j.prp.2019.152572

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center